Navigation Links
ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
Date:1/31/2008

SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), announced today that data from preclinical studies of ANX-201, the Company's broad spectrum antiviral product candidate, has been accepted for presentation at the Keystone Symposia HIV Pathogenesis Conference, which takes place March 27-April 1, 2008 in Banff, Alberta. The HIV Pathogenesis Conference is part of the Keystone Symposia Global Health Series, which is supported by the Bill & Melinda Gates Foundation.

The poster presentation entitled "The pyrophosphate analogue thiophosphonoformic acid confers a favorable HIV resistance profile," is scheduled to be presented on March 30, 2008. The presentation will highlight results of in vitro infectivity assays that demonstrate a unique resistance profile for ANX-201 that suggests suppression of resistance to nucleoside reverse transcriptase inhibitors (NRTIs), a commonly used class of drugs. The potential clinical benefit of ANX-201 when used as part of combination therapy with NRTIs in resistant HIV-infected patients will also be discussed.

About ANX-201

ANX-201 (thiophosphonoformic acid) is a pyrophosphate analog and member of a new class of reverse transcriptase inhibitor (RTI) for treatment of resistant HIV-infected patients. ANX-201 has shown activity against HIV drug-resistant clinical isolates in preclinical studies. The resistance profile of ANX-201 is unique among approved RTIs and has been shown to resensitize NRTI-resistant viruses. In preclinical studies, antiretroviral activity of ANX-201 has demonstrated synergistic activity with NRTIs suggesting potential clinical benefits of combination therapy. In other preclinical studies, ANX-201 has shown broad-spectrum antiviral a
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 /PRNewswire/ ... and Bloom Burton & Co. Ltd. ("Bloom Burton") today ... (the "Lock-Up") 2,353,130 common shares of the Company ("Common ... to the Lock-Up. Of the Common Shares released from ... upon release from the Lock-Up while the remainder will ...
(Date:2/27/2015)... Report Details   ... R&D progress, and predicted revenues ,Where is the market ... commercial prospects for this market and related technologies? Visiongain,s ... trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to restore ...
(Date:2/27/2015)... 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... announced financial results for its first quarter ended December ... ended December 31, 2014, revenue was $1,336,685. Operating expenses ... or $0.02 per share.  Covalon,s President ... very pleased with the significant progress we have made ...
Breaking Medicine Technology:ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... DIEGO, Dec. 22, 2011 ViroPharma Incorporated (NASDAQ: ... exclusive option to acquire Meritage Pharma, Inc., a private company ... suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a ... has paid an initial $7.5 million, and has agreed to ...
... Therapeutics, Inc. (Nasdaq: OREX ) today announced the ... consisted of one share of common stock and a warrant ... to the public of $1.45 per share of common stock ... stock, which together comprised the purchase price of $15.94 per ...
Cached Medicine Technology:ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 2ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 3ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 4ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 5ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 6ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 7Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock 2
(Date:2/27/2015)... Laguna Hills, CA (PRWEB) February 27, 2015 ... has been chosen as their Sage ERP Document Management ... ERP, Sage 300 ERP, Sage CRM and other complimentary ... ADSS Global have worked side-by-side for many years to ... their Sage ERP applications. , “We are thrilled ...
(Date:2/27/2015)... 27, 2015 The V Foundation for ... funding organizations, is excited to announce numerous promotions taking ... and many long-standing partnerships highlight The V Foundation’s significant ... expanding ways for all to get involved. Awarding ... cancer research, The V Foundation has funded more than ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 On February ... “The Real Liquid Botox ,” that details the development ... that is working its way through FDA trials. For those ... cream is very attractive. Of course, if the drug ... prescription at a physician’s office. (see: goo.gl/PQvQwk) , “As the ...
(Date:2/27/2015)... The Dawn Greene Hospice, a 10-bed facility ... (MMW) on the Upper East Side, was officially dedicated and ... His Eminence Timothy Michael Cardinal Dolan. , Thomas J. Fahey, ... and a member of the ArchCare Board of Trustees, presided ... O.Carm, executive director of MMW, and Christina McInerney, president and ...
(Date:2/27/2015)... Calif. (PRWEB) February 27, 2015 The ... and research expertise have made it a beacon of ... and beyond, has been acknowledged by the national society ... the Huntington’s Disease Society of America — as ... , The acknowledgement recognizes the center’s service to over ...
Breaking Medicine News(10 mins):Health News:Altec Announces 2014 Sage ERP Document Management Partner of the Year Award Recipient 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 3Health News:Is Topical Botox the Next Big Thing? 2Health News:The Dawn Greene Hospice Is Officially Dedicated 2Health News:The Dawn Greene Hospice Is Officially Dedicated 3Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 3
... Diego, CA, August 2, 2011 Engaging in physical ... the odds of survival. In a study published in ... Preventive Medicine , researchers from the Israel Study Group ... (MI) survivors who lived in low socioeconomic status (SES) ...
... 29, 2011) − In a recent study published in ... University of Kentucky College of Nursing and Mark Pyles, ... at the College of Charleston, found smoke-free legislation does ... urban communities. This is true regardless of whether the ...
... -- Teens are much more likely to eat junk food ... with many fast food restaurants and other sources of unhealthy ... on junk food consumption by California teens living in neighborhoods ... food restaurants, convenience stores, dollar stores and liquor stores, with ...
... HealthDay Reporter , MONDAY, Aug. 1 (HealthDay News) -- ... after dinner. Play tag with your kids at the park. ... 150 minutes, or 2.5 hours, of moderate activity a week -- ... Those who did more -- about 300 minutes a week, ...
... Blocking a growth factor receptor cripples cancer growth in a ... online on August 1 in the Journal of Experimental ... cases of T cell acute lymphoblastic leukemia (T-ALL) carry genetic ... in aberrant activation of the cell. A study by Andrew ...
... 1, 2011) Two new studies published in the ... (JNM) provide insight into the potential of positron ... and to identify pharmaceuticals to slow the progress of ... the Alzheimer,s Association guidelines for detecting Alzheimer,s-related brain changes ...
Cached Medicine News:Health News:Heart attack survivors from poorer neighborhoods get less exercise 2Health News:Study finds smoke-free laws don't impact rural or urban economies 2Health News:With Junk Food Stores Nearby, Teens May Eat More of It 2Health News:Even a Little Exercise Helps the Heart, Study Finds 2Health News:Even a Little Exercise Helps the Heart, Study Finds 3Health News:New JNM research supports upcoming Alzheimer's disease guidelines 2
1.7/2.2 mm Delta System resorbable implant technology merges science and simplicity for a superior craniomaxillofacial surgery product. The system consists of resorbable bone plates and screws fabric...
... A-scan Sonomed-315 is intended for visualization of ... of midline shifts in the brain, evaluation ... easy to use, the Sonomed-315 offers quick ... mode allows to identify the anatomic structures ...
... a scaleable device that works ... platelet plasma or buffy coat. ... coat must be prepared independently ... Starting volume and concentration factor ...
The Ultrafoam Collagen Sponge is indicated in all surgical procedures as an adjunct to hemostasis when control by ligature or conventional procedures are ineffective or impractical....
Medicine Products: